阿那白滞素治疗儿童与成人Still病
本文综述将全身型幼年特发性关节炎与成人起病Still病视为同一疾病Still病的理由,并基于现有文献评估阿那白滞素的疗效与安全性;27项研究显示应答显著,临床无活动性疾病或等效状态见于23-100%的患者,糖皮质激素减量或停用在各研究中普遍报告。
要点
- 27项研究显示阿那白滞素在Still病中应答显著,临床无活动性疾病或等效状态为23-100%。
- 各研究普遍报告糖皮质激素减量或停用。
- 儿科患者早期或一线使用阿那白滞素时,临床无活动性疾病及成功减停阿那白滞素见于>50%的患者。
核心结论
- 现有数据支持阿那白滞素用于Still病的靶向治疗,可改善临床结局,尤其在疾病早期启动时。
- 将全身型幼年特发性关节炎与成人起病Still病视为同一疾病Still病具有依据,仅发病年龄不同。
研究设计与样本
- 本文为综述,基于现有文献分析27项研究,评估阿那白滞素在Still病中的疗效与安全性。
- 欧洲药品管理局(EMA)近期批准阿那白滞素用于Still病。
主要发现
- 27项研究分析显示,Still病患者对阿那白滞素应答显著,临床无活动性疾病或等效状态报告为23-100%。
- 各研究普遍报告糖皮质激素减量或停用。
- 在早期或一线使用阿那白滞素的儿科患者研究中,临床无活动性疾病及成功减停阿那白滞素见于>50%的患者。
关键数值与推荐
- 临床无活动性疾病或等效状态:23-100%的患者(27项研究分析)。
- 儿科早期或一线使用研究中,临床无活动性疾病及成功减停阿那白滞素:>50%的患者。
临床怎么用
- 对Still病患者可考虑阿那白滞素靶向治疗,尤其应在疾病早期启动以改善临床结局。
- 治疗中可预期糖皮质激素减量或停用,并在儿科早期或一线使用中关注阿那白滞素的减停。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic juvenile idiopathic arthritis and adult-onset Still's disease are rare autoinflammatory disorders with common features, supporting the recognition of these being one disease-Still's disease-with different ages of onset. Anakinra was recently approved by the European Medicines Agency for Still's disease. In this review we discuss the reasoning for considering Still's disease as one disease and present anakinra efficacy and safety based on the available literature. The analysis of 27 studies showed that response to anakinra in Still's disease was remarkable, with clinically inactive disease or the equivalent reported for 23-100% of patients. Glucocorticoid reduction and/or stoppage was reported universally across the studies. In studies on paediatric patients where anakinra was used early or as first-line treatment, clinically inactive disease and successful anakinra tapering/stopping occurred in >50% of patients. Overall, current data support targeted therapy with anakinra in Still's disease since it improves clinical outcome, especially if initiated early in the disease course.
引用
- Vastert SJ, Jamilloux Y, Quartier P, et al. Anakinra in children and adults with Still's disease. Rheumatology (Oxford). 2019. PMID: 31769856. doi:10.1093/rheumatology/kez350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。